Levosimendan administration is not associated with increased risk of bleeding and blood transfusion requirement in patients undergoing off-pump coronary artery bypass grafting: a retrospective study from single center.

Li-Hong WangXiao-Hong WangJie-Chao TanLi-Xian HeRun-Qiao FuYong LinYun-Tai Yao

Published in: Perfusion (2021)

LEVO administration was neither associated with more postoperative blood loss nor increased allogeneic blood transfusion requirement in OPCAB patients.

Keyphrases

coronary artery bypass grafting
patients undergoing
end stage renal disease
percutaneous coronary intervention
ejection fraction
coronary artery disease
newly diagnosed
chronic kidney disease
bone marrow
peritoneal dialysis
acute coronary syndrome
hematopoietic stem cell